Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Receivables (2019 - 2024)

Pliant Therapeutics (PLRX) has disclosed Receivables for 6 consecutive years, with $2.3 million as the latest value for Q4 2024.

  • On a quarterly basis, Receivables fell 23.19% to $2.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was $2.3 million, a 23.19% decrease, with the full-year FY2024 number at $2.3 million, down 23.19% from a year prior.
  • Receivables was $2.3 million for Q4 2024 at Pliant Therapeutics, down from $3.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $18.6 million in Q4 2020 to a low of $1.6 million in Q3 2021.
  • A 5-year average of $4.5 million and a median of $2.7 million in 2021 define the central range for Receivables.
  • Peak YoY movement for Receivables: plummeted 88.69% in 2021, then skyrocketed 190.11% in 2022.
  • Pliant Therapeutics' Receivables stood at $18.6 million in 2020, then plummeted by 87.17% to $2.4 million in 2021, then increased by 28.45% to $3.1 million in 2022, then decreased by 2.09% to $3.0 million in 2023, then fell by 23.19% to $2.3 million in 2024.
  • Per Business Quant, the three most recent readings for PLRX's Receivables are $2.3 million (Q4 2024), $3.0 million (Q4 2023), and $2.0 million (Q3 2023).